Evidence map›Paper›PMID 41476550›Full record

ArticleACS omega2025

Comparative Binding Affinities of Platinum-Based Drugs toward Purine Alkaloids and Nucleobases.

Beata Szefler, Kamil Szupryczyński

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Beata SzeflerDepartment of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpińskiego 5 Street, 85-096 Bydgoszcz, Poland.ORCID https://orcid.org/0000-0001-8433-3520
Kamil SzupryczyńskiDoctoral School of Medical and Health Sciences, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Jagiellońska 13 street, 85-067 Bydgoszcz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum-based anticancer drugs are among the most commonly used agents in cancer therapy. In particular, carboplatin, cisplatin, and oxaliplatin have been used in both monotherapies and combination therapies for many years. The main targets of these compounds are nucleobases in DNA. By creating cross-links, they inhibit cell development and lead to apoptosis. Recent studies indicate that platinum-(II) drugs can interact with other compounds with structures similar to nucleobases. For this reason, the current study analyzed the interactions of carboplatin, cisplatin, and oxaliplatin with nucleobases and purine alkaloids (caffeine, theobromine, theophylline) using spectroscopic and computational chemistry methods. Theoretical studies indicated that cytostatics exhibit affinity not only for nucleobases but also for purine alkaloids. However, cytostatics more easily form complexes with nucleobases compared with alkaloids. Experimental investigations confirmed the results of these theoretical studies.

Identifiers

PMID41476550
PMCPMC12750210

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.